Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

• Status: Terminated
• Trial end date: 2019-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

• To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wills Eye
• Collaborator: University of Medicine and Dentistry of New Jersey
• Treatments: Lubricant Eye Drops; Timolol

Criteria

Inclusion criteria:

• Age from 2 years to 10 years

• Port-Wine Mark

• English fluent and literate substitute decision maker

• Substitute decision maker vision sufficient to read informed consent document

Exclusion criteria:

• Active ocular infection (conjunctivitis, keratitis,)

• History of systemic conditions including hypo/hypertension, hypoglycemia, bradycardia, asthma or any contraindication to beta blocker use

• Unable to comply with required follow-up

• Substitute decision maker not English fluent or not literate

• Substitute decision maker unable to read consent document

• Patient already using systemic beta-blocker or beta-agonist (Patients already using topical beta-blocker for glaucoma will not be excluded from study).